Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Condition

Maroteaux-Lamy syndrome

Endocrine, Nutritional and Metabolic Diseases

Maroteaux-Lamy syndrome, also known as mucopolysaccharidosis type VI or MPS VI, is an inherited lysosomal storage disease caused by a deficiency of the enzyme arylsulfatase B, or ARSB, which is needed to break down glycosaminoglycans, specifically dermatan sulfate and chondroitin sulfate. Without enough ARSB activity, these substances build up inside cell lysosomes, causing progressive symptoms. Unlike most other mucopolysaccharidosis disorders, children with Maroteaux-Lamy syndrome typically have normal intelligence, but they can develop a range of physical complications, including macrocephaly, hydrocephalus, coarse facial features, heart valve disease, an enlarged liver and spleen, and umbilical hernia. It is caused by mutations in the ARSB gene and is inherited in an autosomal recessive pattern. Onset is at birth, with symptoms appearing in early childhood; the condition is lifelong, and heart disease and airway obstruction are its major causes of reduced life expectancy. It falls under endocrinology and is also called polydystrophic dwarfism.

Facts
Classification
ICD-10 Chapter
IV: Endocrine, Nutritional and Metabolic Diseases 1
Communicable or Non-communicable
Non-Communicable 2
Causative Agent
Causative Agent (category)
Genetic / Hereditary 2
Sources
1. Wikidata: Maroteaux-Lamy syndrome
Wikidata P494 (E76.2)View the Source
2. Maroteaux-Lamy syndrome (Wikipedia)
  • Infobox: causes
    Mutations in the ARSB gene
  • Lead: disease category
    Maroteaux-Lamy syndrome, or mucopolysaccharidosis type VI (MPS-VI), is an inherited disease caused by a deficiency in the enzyme arylsulfatase B (ARSB).
View the Source
Maroteaux-Lamy syndrome (Wikipedia)
Lead section
Quote, Lead section
Maroteaux-Lamy syndrome, or mucopolysaccharidosis type VI (MPS-VI), is an inherited disease caused by a deficiency in the enzyme arylsulfatase B (ARSB).
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.